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washed three times with HBSS containing 0.5mg/mL heparin sulfate,
detached with accutase, and resuspended in growth media for analysis.
Cell-associated ﬂuorescence was measured via ﬂow cytometry. Live cells
were discriminated via forward and side scatter; cell association was
quantiﬁed using the mean ﬂuorescence intensity (MFI). At each dosage,
MFI values between control and TAT-peptides were compared using
paired t-tests with an a priori signiﬁcance level of 0.05.
Results: The TAT-PTD resulted in signiﬁcantly more cell-associated
ﬂuorescence than the control peptide in a dose-dependent manner
implying that intracellular uptake was facilitated. The MFI values
for TAT-Treated cells (MFI: 313±61, 686±136, 2430±271 for peptide
concentrations of 1.25, 2.5, and 5mM, respectively) were signiﬁcantly
greater than those (110±15, 156±25, 280±36 for 1.25, 2.5, and 5mM,
respectively) for the chondrocytes treated with the control peptide (all
p ≤ 0.02). Cell association of TAT peptides was observed in various types
of chondrocytes from both male and female donors, from donors ranging
in age from 24 to 64, and from normal and OA donors.
Conclusions: These data suggest that the TAT protein transduction
domain facilitates peptide-uptake in primary human chondrocytes from
diverse donor populations with varying age and OA grades. Future studies
will determine whether the TAT PTD can be used to deliver therapeutic
molecules to in vivo articular cartilage for modulating chondrocyte
behavior toward treating osteoarthritis.
496
PHELLODENDRON AMURENSE REGULATE THE LEVELS OF MATRIX
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(MAPK) PATHWAY IN HUMAN OSTEOARTICULAR CARTILAGE AND
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Purpose: Traditional medicine has widely been used Phellodendron
amurense Rupr. (Rutaceae) to treat various inﬂammatory diseases
including arthritis. In this study, we investigated the effects of
Phellodendron amurense (P. amurense) in protecting cartilage, including
regulating the levels of aggrecanases, matrix metalloproteinases
(MMPs)/tissue inhibitor of metalloproteinase (TIMP), proinﬂammatory
cytokines and signaling of the mitogen activated protein kinase (MAPK)
pathway in human osteoarticular cartilage and chondrocytes.
Methods: Explants from human osteoarthritis cartilage were cultured
alone or in IL-1a for 7 days with or without P. amurense ethanol
extract or celecoxib (40, 100, 200mg/ml). The effect of P. amurense on
matrix degradation induced by IL-1a in human articular cartilage was
assessed by staining, and the quantities of sulfated glycosaminoglycan
(GAG) and type II collagen were calculated from the culture media.
The levels of aggrecanases, MMPs, TIMP, and PGE2 in the culture
media were investigated using an enzyme-linked immunosorbent assay
(ELISA). In addition, reverse transcription polymerase chain reaction (RT-
PCR) evaluated the mRNA expression of aggrecanases, MMPs and TIMP.
Furthermore, Western blot analysis was performed to identify the roles
that P. amurense played in the ERK, JNK and p38 signaling pathways.
Results: P. amurense showed no evident cytotoxicity on human
articular cartilage. P. amurense signiﬁcantly inhibited the IL-1a-induced
degradation of GAG and type II collagen from human osteoarticular
cartilage in a concentration-dependent manner. Celecoxib did not
signiﬁcantly inhibit IL-1a-induced release of GAG and only slightly
reduced type II collagen. P. amurense also dose-dependently decreased
the levels of aggrecanase-1 and -2, MMP-1, -3, and -13, whereas it
increased TIMP-1 expression in human osteoarticular cartilage. Celecoxib
only decreased MMP-1 and MMP-13 levels in human osteoarticular
cartilage. In addition, P. amurense reduced the phosphorylation of
extracellular signal regulated kinase (ERK)1/2, Jun NH2-terminal kinase
(JNK) and activated phospho-p38 MAPK in a dose-dependent manner in
human osteoarthritic chondrocytes.
Conclusions: P. amurense inhibited osteoarticular cartilage and
chondrocyte destruction by inhibiting proteoglycan release and type
II collagen degradation, down-regulating aggrecanases, MMP activities
and phospho-ERK1/2, JNK and p38 MAP kinase signalling, and up-
regulating TIMP-1 activity. Therefore, our results suggest that P. amurense
is a potential therapeutic agent to protection cartilage against OA
progression.
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Purpose: To evaluate the patterns of therapy switching, add-on and
discontinuation after initiation of treatment with select currently
recommended treatments in patients with OA.
Methods: Using the United Kingdom THIN (The Health Improvement
Network) database, patients at least 18 years of age, with at
least two healthcare encounters with an associated diagnosis of
OA starting January 1, 2005, with the two diagnoses being at
least 30 days apart, newly prescribed (index event) non-selective
nonsteroidal anti-inﬂammatory drugs (NS-NSAIDs, N =6,639; average age
± SD, 67.2±11.4 years), Cyclooxygenase-2 inhibitors (Cox-2s, N =542;
68.0±11.2 years), acetaminophen (N=3,215; 74.1±10.1 years), tramadol
(N=1,724; 70.1±11.2 years), weak opioids (N=5,886; 70.4±11.1 years)
and strong opioids (N=178; 74.0±11.3 years) within 30 days prior,
or anytime after the ﬁrst diagnosis of OA were selected. Descriptive
statistics, Kaplan Meier analyses, and COX proportional hazards model
were used to evaluate patterns of therapy switching, add-on, and discon-
tinuation during the 12-months post-index period. The study protocol
was approved by the Cambridgeshire 4 Research Ethics Committee.
Results: Substantial proportions of OA patients switched therapy within
a year after treatment initiation and rates of therapy switching were
signiﬁcantly different (p < 0.0001) across the evaluated drugs groups: NS-
NSAIDs, 30.0%; Cox-2s, 44.6%; acetaminophen, 32.8%; tramadol, 57.8%;
weak opioids, 33.7%; and strong opioids, 59.6%. Patterns of therapy
add-on at 12-months were also signiﬁcantly (p < 0.0001) different,
although rates of therapy add-on were much lower: NS-NSAIDs, 9.1%;
Cox-2s, 13.5%; acetaminophen, 9.1%; tramadol 11.8%; weak opioids,
8.7%; and strong opioids, 15.2%. A majority of patients in each group
discontinued therapy during the 12-months post-index period (91.9%,
86.9%, 91.4%, 89.7%, 93.2%, and 84.3% of patients in the NS-NSAIDs, Cox-
2s, acetaminophen, tramadol, weak opioids and strong opioids groups,
respectively). An evaluation of estimated probabilities suggested that
over two thirds of patients who switched, augmented or discontinued
therapy did so within the ﬁrst 2-months, and a majority did so within
6-months of treatment initiation.
Conclusions: Results of this study suggest that therapy switching
and discontinuation were very common among OA patients initiating
treatment with the currently recommended medication classes for
this painful condition. The observed high rates of therapy switching
and discontinuation may be indicative of inadequate pain relief or
potentially intolerable side-effects of therapies. Given the human and
economic burden of OA, future research may beneﬁt from a focus
on comparative efﬁcacy and safety parameters to further differentiate
treatment options.
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Purpose: Osteoarthritis is a multifactorial disease characterized by
loss of articular cartilage and subchondral plate thickening. Therefore,
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biochemical analysis of the underlying bone tissue has provided
important information for treatment of osteoarthritis. In this study, we
determined the potential role of formononetin, a phytoestrogen isolated
from Astragalus membranaceus to alter the expression of metabolic
markers and cytokine production of human normal osteoblasts (Obs)
and osteoarthritis subchondral osteoblasts (OA Obs).
Methods: Human OA Obs and normal Obs were cultured for 3 days,
7 days or 14 days in presence medium only or were treated with various
doses of formononetin. Cells were analyzed for viability by WST-8 assay,
alkaline phosphatase (ALP) activity, osteogenic markers (osteocalcin
(OCN) and type I collagen (Col I)) and cytokines (interleukin-6 (IL-6),
vascular endothelial growth factor (VEGF), bone morphogenic protein-2
(BMP-2)). The level of IL-6, VEGF, BMP-2, OCN and Col I was increased
in OA Obs compared with normal Obs.
Results: Formononetin dose-dependently decreased ALP, IL-6, VEGF,
BMP-2, OCN and Col I in OA Obs, while markedly increased ALP,
VEGF, BMP-2, OCN and Col I in normal Obs. Interestingly, formononetin
markedly increased the expression of VEGF and BMP-2 for 3 days
of culture and signiﬁcantly increased OCN and Col I at 14 days in
human normal Obs. The remodeling effect of formononetin on osteogenic
markers and cytokines of inﬂammatory mediators was more striking in
OA Obs as well.
Conclusions: These results could suggest that formononetin has biphasic
positive effects on normal Obs and OA Obs by modifying their biological
synthetic capacities.
Acknowledgement: This work was supported by the National Research
Foundation of Korea Grant funded by the Korean Government (2010–
0024833).
499
OPEN-LABEL, OPEN-ENDED STUDY OF THE SAFETY OF DICLOFENAC
TOPICAL SOLUTION FOR MANAGEMENT OF OSTEOARTHRITIS:
CHARACTERIZATION OF GASTROINTESTINAL ADVERSE EVENTS
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Purpose: Oral nonsteroidal anti-inﬂammatory drugs (NSAIDs) are
effective for the treatment of osteoarthritis (OA), but their chronic
use is associated with serious gastrointestinal (GI), cardiovascular, and
potentially other systemic adverse events (AEs). Diclofenac topical
solution (TDiclo) has demonstrated efﬁcacy similar to oral diclofenac
(ODiclo) in randomized, double-blind, clinical trials in OA of the knee,
with fewer GI AEs. The incidence of GI AEs occurring with TDiclo in
patients in an ofﬁce setting was analyzed using safety data from a
Canadian compassionate-use treatment program of TDiclo for OA.
Methods: In this multicenter, open-label, open-ended, compassionate-
use, Phase 3 study, patients with physician-diagnosed OA were instructed
to apply 5 drops (small joint, eg, knuckle), 20 drops (medium joint, eg,
wrist), or 40 drops (large joint, eg, knee) of TDiclo to the affected joint
4 times daily in an uncontrolled, real-world setting. Follow-up safety
assessments were scheduled at 1, 3, 6, and 12 months, and yearly
thereafter. At each visit, patients were asked open-ended questions
regarding the onset and nature of any AE that occurred since the last
visit. It was at the patient’s discretion whether to contact the investigator
at the onset of an AE or wait until the next visit.
Results: A total of 4213 patients were evaluated. The duration of exposure
to TDiclo extended over 6–12 months in 12.4% and ≥12 months in 19.8%.
A GI AE occurred in 35 (0.8%) patients; the most frequently reported were
dyspepsia (0.4%), nausea (0.2%), and diarrhea (0.1%). A GI AE was listed
as a reason for study discontinuation in 23 patients (0.5%). None of the
GI AEs that occurred during the study were deemed by the investigator
to be related to TDiclo treatment.
Conclusions: In an uncontrolled ofﬁce-practice setting, the occurrence
of GI AEs in patients receiving TDiclo was low. No individual GI AE was
reported in >0.4% of patients, and few patients discontinued therapy
because of these events. The results of this open-label study demonstrate
that TDiclo is a well-tolerated therapeutic option for those patients who
wish to reduce their likelihood of experiencing the GI AEs that are
commonly associated with oral NSAIDs.
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Purpose: Randomized, double-blind trials of diclofenac topical solution
(TDiclo) in osteoarthritis (OA) of the knee have demonstrated efﬁcacy
similar to oral diclofenac, with fewer systemic adverse events (AEs). The
most common AEs occurring with TDiclo were application-site reactions.
To characterize these reactions in a clinical setting, safety data were
analyzed in patients who received TDiclo in a Canadian compassionate-
use treatment program for OA.
Methods: This was a multicenter, open-label, open-ended study
conducted in Canada. Patients with physician-diagnosed OA were
instructed to apply 5 drops (small joint, eg, knuckle), 20 drops (medium
joint, eg, wrist), or 40 drops (large joint, eg, knee) of TDiclo, 4 times
daily. Follow-up safety assessments were scheduled at 1, 3, 6, and
12 months, and yearly thereafter. At each visit, the investigator asked
the patient open-ended questions about any AE occurring since the
last visit, assessed the application site for signs of irritation and scored
it (0 = no visible reaction; 0.5 = equivocal response, itching burning
sensation, pruritus; 1 = mild erythema; 2 = intense erythema; 3 = intense
erythema with edema; and 4 = intense erythema with edema and
vesicular eruption).
Results: A total of 4213 patients were enrolled. The duration of exposure
to TDiclo extended over 6–12 months in 12.4% and ≥12 months in
19.8%. The most common AEs were application-site reactions in 112
of the 4213 patients (2.7%), which included rash (1.2%), dry skin (0.6%),
and pruritus (0.5%). Data regarding skin irritation score were available
for 1923 patients; of these, 1798 (93.5%) had a score of 0 (no visible
reaction), 59 (3.1%) had a score of 0.5 (equivocal response, itching,
burning sensation); and 48 (2.5%) had a score of 1 (mild erythema).
A score of 2 (intense erythema) was recorded in 7 (0.4%) and a score
of 3 (intense erythema with edema) in 6 (0.3%) patients; a score of 4
(intense erythema with edema and vesicular eruption) was recorded in
only 5 patients (0.3%). A total of 40 patients (0.9%) reported discontinuing
treatment because of an application-site reaction. No data were collected
on potential patient interventions such as emollients or creams.
Conclusions: Consistent with published controlled, clinical trials, the
most common AEs in individuals with OA treated with TDiclo in clinical
practice were skin-related. Their occurrence was low, and few patients
discontinued treatment because of these reactions. Given the risk of
systemic AEs associated with oral diclofenac, TDiclo has obvious potential
for the reduction of adverse effects.
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Purpose: Nitric oxide (NO), namely resulting from the activity of the
inducible nitric oxide synthase (iNOS) whose expression is increased
in osteoarthritic chondrocytes, is an important component of the
mechanisms that lead to cartilage degradation and inﬂammation,
the hallmarks of OA. Overexpression of iNOS and the subsequent
increased production of NO mediates, at least in part, the inhibition
of matrix synthesis and promotion of its degradation induced by pro-
inﬂammatory and catabolic cytokines, like interleukin-1b (IL-1), in
articular chondrocytes. Thus, inhibition of NO production and iNOS
expression are considered important targets for the development of anti-
osteoarthritic therapies. Essential oils are composed of a wide diversity
of hydrophobic low molecular weight compounds with favorable
pharmacokinetic properties that make them especially suited collections
for drug screening. Here we report results on a screening of the ability
of ﬁve essential oils to inhibit IL-1-induced iNOS expression and NO
production in human chondrocytes.
